4D Path is Revolutionizing Cancer with Next Generation Tumor Response Prediction
4D Path is fueling future advances in cancer therapeutics with its QPOR™ platform, which is designed to accurately predict a patient’s response to cancer treatment from digitized images of a standard H&E-stained biopsy
Ground-Breaking
Using a unique combination of statistical physics and a deep understanding of cancer biology, 4D Path’s technology can quantify cell cycle deregulations, a hallmark of cancer. Prior to 4D Path, no other technology has been able to measure these intra/inter tumor dynamics. Unlike existing cancer diagnostics which infer potential response based on molecular driver(s) of disease, this approach accounts for and quantifies the impact of complex multi-system interplay that is fundamental to cancer biology.
Comprehensive & Expansive
With 29+ unique and combinatorial continuous scale indices, 4D Path’s technology can capture the collective biological signature to provide a comprehensive understanding of the individual tumor state, thereby guiding truly personalized therapy response prediction.
Demonstrated Proof-of-Concept
4D Path has completed multiple clinically relevant studies with improved therapeutic response prediction based on refined patient stratification including breast cancer trials with Dana-Farber Cancer Institute (DFCI) and the Translational Breast Research Consortium (TBCRC) as well as a study focused on Immunotherapy in advanced metastatic melanoma with Leeds Teaching Hospital.
Strategic Partners
4D Path’s platform is designed to identify patients who will respond to certain therapies. 4D Path is collaborating with cancer researchers and biopharma companies to accelerate discovery and development and improve their clinical, regulatory and commercial success.
Platform Fast Facts
- From digitized H&E-stained images, measures biological signatures to predict response to therapy and additional diagnostic and prognostic insights
- Therapy and tumor agnostic: works across drug classes and tumor types
- 29+ continuous scale indices, including those measuring DNA and proteins, immune profiling, thermodynamics and combinatorial scales
- US patent on full technology with first action allowance
- FDA Breakthrough Device Designation for adjunct diagnostic tests in breast cancer; building clear regulatory path
- Fully automated, highly scalable, end-to-end cloud-based platform.
- Easily integrates into existing pathology-oncology workflows, PACS, digital pathology platforms, EHS systems, scanner infrastructure; hardware agnostic
- ISO Certified; HIPPA and GDPR compliant
